Advertisement

Antiretrovirale Kombinationstherapie bei HIV-1-Infektion und Therapie HIV-assoziierter Komplikationen

  • M. von Depka Prondzinski
  • I. Scharrer
Conference paper

Zusammenfassung

AZT ist die derzeit wirksamste unter den verfügbaren Substanzen in der Vorbeugung HIV-1-assoziierter Morbidität und Mortalität therapienaiver Patienten [1–4]. Unter bestimmten Voraussetzungen scheinen ddI [5–7] und ddC [8–10] eine AZT äquivalente Effektivität zu besitzen. Es gibt Hinweise, daß auch Foscarnet antiretrovirale Wirkung gegen HIV-1 entfaltet [11–16]. In jüngster Zeit haben Kombinationsschemata mit zwei oder mehr Reverse-Transkriptase-Inhibitoren bei fortgeschrittener HIV-1-Infektion länger anhaltende und ausgeprägtere CD4-Zell-Anstiege demonstriert als die Monotherapie bzw. alternierende Gabe [17–26].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Fischl MA, Riehman DD, Grieco MH et al (1987) The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 317: 185–191PubMedCrossRefGoogle Scholar
  2. 2.
    Jackson GG, Paul DA, Falk LA et al (1988) Human immunodeficiency virus (HIV) an- tigenemia (p24) in the acquired immunodeficiency syndrom (AIDS) and the effect of treatment with zidovudine (AZT). Ann Intern Med 108: 175–180PubMedGoogle Scholar
  3. 3.
    Cooper DA, Gatell JM, Kroon S et al (1993) Zidovudine in persons with asymptomatic HIV infection and CD 4+ cell counts greater than 400 per cubic millimeter. N Engl J Med 329: 297–303PubMedCrossRefGoogle Scholar
  4. 4.
    Volberding PA, Lagakos SW, Koch MA et al (1990) Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med 322: 941–949PubMedCrossRefGoogle Scholar
  5. 5.
    Kahn J (1993) New developments in the clinical use of didanosine. J Acquir Immune Defic Syndr 6 (Suppl 1): 47–50Google Scholar
  6. 6.
    Shelton MJ, O-Donnell AM, Morse GD (1992) Didanosine. Ann Pharmacother 26: 660–670PubMedGoogle Scholar
  7. 7.
    Allan JD, Connolly KJ, Fitch H et al (1993) Long-term follow-up of didanosine ad-ministered orally twice daily to patients with advanced human immunodeficiency virus infection and hematologic intolerance of zidovudine. Clin Infect Dis 16 (Suppl 1): 46–51CrossRefGoogle Scholar
  8. 8.
    Abrams DI, Goldman AI, Launer C et al (1994) A comparative trial of Didanosine or Zalcitabine after treatment with Zidovudine in patients with human immunodeficiency virus infection. New Engl J Med 330: 657–662PubMedCrossRefGoogle Scholar
  9. 9.
    Broder S, Yarchoan R (1990) Dideoxycytidine: current clinical experience and future prospects. A summary. Am J med 88: 31S–33SGoogle Scholar
  10. 10.
    Toglhofer W (1992) Neue, in Österreich registrierte Spezialitäten. Hivid (2’,3’-Didesoxycytidin; ddC). Wien Klin Wochenschr 104: 363–367PubMedGoogle Scholar
  11. 11.
    Herst CV, Ondrasik J, Redding K, Ussery F (1991) Effects of foscarnet on HIV P24 antigen levels in vivo in AIDS patients with cytomegalovirus (CMV) retinitis. Int Conf AIDS 1991 Jun 16–21 7: 212Google Scholar
  12. 12.
    Vrang L, Oberg B, Lower J, Kurth R (1988) Reverse transcriptases from human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus (SIV-MAC) are susceptible to inhibition by foscarnet and 3’-azido-3’-deoxythymidine triphosphate. Antimicrob Agents Chemother 32: 1733–1734PubMedGoogle Scholar
  13. 13.
    Gaub J, Pedersen C, Poulsen AG et al (1987) The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients. AIDS 1: 27–33PubMedGoogle Scholar
  14. 14.
    Koshida R, Vrang L, Gilljam G et al (1989) Inhibition of human immunodeficiency virus in vitro by combinations of 3’-azido-3’-desoxythymidine and foscarnet. Antimicrob Agents Chemother 33: 778–780PubMedGoogle Scholar
  15. 15.
    Jacobson MA, Crowe S, Levy J et al (1988) Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS. J Infect Dis 158: 862–865PubMedGoogle Scholar
  16. 16.
    Jacobsen MA, van der Horst C, Causey DM et al (1991) In vivo additive antiretroviral effect of combined zidovudine and foscarnet therapy for human immunodeficiency virus infection (ACTG Protocol 053). J Infect Dis 163: 1219–1222PubMedCrossRefGoogle Scholar
  17. 17.
    Shirasaka T, Yarchoan R, O’Brien MC et al (1993) Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, didesoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc Natl Acad Sci 90: 562–566PubMedCrossRefGoogle Scholar
  18. 18.
    Barr MR, Torres RA, Shay W et al (1992) Case control study of didesoxycytidine (ddC), didanosine (ddl) and zidovudine (AZT) in patients with late stage HIV disease. Int Conf AIDS 1992 Jul 19–24 8: B87Google Scholar
  19. 19.
    Shirasaka T, Yarchoan R, O’Brien M et al (1992) HIV-1 drug-resistance profile in vivo: a comparison of azidothymidine (AZT), didesoxycytidine (ddC), and didesoxyinosine (ddI). Int Conf AIDS 1992 Jul 19–24 8: B182Google Scholar
  20. 20.
    Shirasaka T, Yarchoan R, Husson R et al (1991) HIV may develop resistance preferentially to adzidothymidine (AZT) as compared to didesoxycytidine (ddC) and didesoxyinosine (ddI) in patients receiving antiviral therapy. Int Conf AIDS 1991 Jun 16–21 7: 24Google Scholar
  21. 21.
    Yarchoan R, Pluda JM, Perno CF et al (1990) Initial clinical experience with didesoxynucleosides as single agents and in combination therapy. Ann N Y Acad Sci 616: 328–343PubMedCrossRefGoogle Scholar
  22. 22.
    Dolin R, Amato D, Fischl M et al (1993) Efficacy of Didanosine (ddI) versus Zidovudine (ZDV) in patients with no or ≤16 weeks of prior ZDV therapy. IXth International Conference on AIDS, Berlin Jne 6–11, 1993 WS-B24-1Google Scholar
  23. 23.
    Ragni M, Dafni R, Amato DA et al (1992) Combination zidovudine and didesoxyinosine in asymptomatic HIV(+) patients. Int Conf AIDS 1992 Jul 19–24 8: Mol5Google Scholar
  24. 24.
    Merigan TC (1991) Treatment of AIDS with combinations of antiretroviral agents. Am J Med 90: 8–17CrossRefGoogle Scholar
  25. 25.
    Kahn JO, Lagakos SW, Richman DD et al (1992) A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. N Engl J Med 327: 581–587PubMedCrossRefGoogle Scholar
  26. 26.
    Connolly KJ, Allan JD, Fitch H et al (1991) Phase I study of 2’-3’-didesoxyinosine ad-ministered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine. AM J Med 91: 471–478PubMedCrossRefGoogle Scholar
  27. 27.
    Reddy MM, Grieco MH, McKinley GF et al (1992) Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis. J Infect Dis 166: 607–610PubMedCrossRefGoogle Scholar
  28. 28.
    Bergdahl S, Sonnerborg A, Larsson A et al (1988) Declining levels of HIV P24 antigen in serum during treatment with foscarnet [letter]. Lancet 1: 1052PubMedCrossRefGoogle Scholar
  29. 29.
    Bühles WC jr, Mastre BJ, Tinker AJ et al (1988) Ganciclovir treatment of life- or sight- threatening cytomegalovirus infection: experience in 314 immunocompromised patients. Rev Infect Dis 10 (Suppl 3): 495–506CrossRefGoogle Scholar
  30. 30.
    Bueno S, Souza R, Sampaio P et al (1992) Ganciclovir toxicity in treatment of AIDS patients with cytomegalovirus retinitis. Int Conf AIDS 1992 Jul 19–24 8: B111Google Scholar
  31. 31.
    Nussbaum J, Antoniskis D, Causey D, Leedom JM (1989) Toxicity of combined AZT/gancyclovir (DHPG) therapy in AIDS patients. Int Conf AIDS 1989 Jun 4–9 5: 195Google Scholar
  32. 32.
    Jacobson MA, Owen W, Campbell J et al (1993) Tolerability of combined ganciclovir and didanosine for the treatment of cytomegalovirus disease associated with AIDS. Clin Infect Dis 16 (Suppl 1): 69–73CrossRefGoogle Scholar
  33. 33.
    Höchster H, Dietrich D, Bozzette S et al (1990) Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. An AIDS Clinical Trials Group Study. Ann Intern Med 113: 111–117PubMedGoogle Scholar
  34. 34.
    Luft BJ, Brooks RG, Conley FK et al (1984) Toxoplasmic encephalitis in patients with acquired immune deficiency syndrome. JAMA 252: 913–917PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • M. von Depka Prondzinski
  • I. Scharrer

There are no affiliations available

Personalised recommendations